Acute Lung Injury Market Report 2026

The acute lung injury market size has grown steadily in recent years. It will grow from $2.59 billion in 2025 to $2.71 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to high prevalence of pneumonia and trauma-related lung injuries, limited access to advanced ventilation systems, growing critical care awareness, adoption of standard fluid management protocols, reliance on hospital-based therapies.

The acute lung injury market size is expected to see steady growth in the next few years. It will grow to $3.19 billion in 2030 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to development of novel pharmacotherapies for ALI, increasing integration of ai in patient monitoring, expansion of intensive care units globally, rising adoption of personalized treatment plans, advancement in minimally invasive ventilation technologies. Major trends in the forecast period include rising incidence of acute lung injury cases globally, increased adoption of mechanical ventilation technologies, growing use of pharmacotherapy and fluid management, focus on early diagnosis and monitoring tools, expansion of hospital-based critical care facilities.

The rising prevalence of respiratory diseases is expected to drive the growth of the acute lung injury market going forward. Respiratory diseases encompass a group of conditions that affect the lungs and other parts of the respiratory system, resulting in difficulty breathing and impaired lung function. The increasing prevalence of respiratory diseases is influenced by factors such as rising air pollution, smoking, sedentary lifestyles, aging populations, and the impact of viral infections. Respiratory conditions, including pneumonia, contribute to acute lung injury by causing severe inflammation and damaging the alveoli, which leads to impaired gas exchange and respiratory distress. For instance, in October 2024, according to the National Asthma Council, an Australia-based non-profit organization, Australia recorded 474 asthma-related deaths in 2023, including 325 females and 149 males. This number is nearly identical to the 473 asthma-related deaths reported in 2022, indicating a consistent trend in asthma mortality over the two years. Therefore, the rising prevalence of respiratory diseases is fueling growth in the acute lung injury market.

Major companies operating in the acute lung injury treatment market are focusing on developing advanced solutions, such as recombinant human plasma gelsolin (rhu-pGSN), to restore immune balance, regulate critical inflammatory responses, and potentially improve outcomes in severe lung injury. Recombinant human plasma gelsolin (rhu-pGSN) is derived from gelsolin, a highly conserved protein that plays a key role in controlling immune dysregulation in acute respiratory distress syndrome (ARDS). For instance, in June 2025, BioAegis Therapeutics, a US-based biotech company, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead product candidate, rhu-pGSN, for the treatment of ARDS. This therapy provides unique benefits, including rebalancing dysfunctional inflammation without suppressing immune function, regulating critical immune responses in the lungs, and potentially improving outcomes for patients with severe inflammatory lung injury.

In September 2024, Ligand Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Apeiron Biologics AG for $100 million. This acquisition strengthens Ligand’s portfolio by adding innovative therapies, particularly in immunotherapy and cancer treatment, and expands its research and development capabilities, creating potential for new revenue streams and reinforcing its position in the biotech industry. Apeiron Biologics AG is an Austria-based biotechnology company engaged in developing treatments for acute lung injury (ALI).

Major companies operating in the acute lung injury market are Medtronic plc, Baxter International Inc., GE Healthcare Technologies Inc., Drägerwerk AG & Co. KGaA, Getinge AB, Koninklijke Philips N.V., Hamilton Medical AG, Vyaire Medical Inc., Vapotherm Inc., GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Faron Pharmaceuticals Oy, Windtree Therapeutics Inc., Apeiron Biologics AG, ReAlta Life Sciences Inc., Vasomune Therapeutics Inc., MediciNova Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc.

North America was the largest region in the acute lung injury market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute lung injury market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute lung injury market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the acute lung injury market by increasing costs for imported mechanical ventilators, monitoring devices, and pharmacological agents. Hospital and clinic segments relying on high-end imported equipment, particularly in north america, europe, and asia-pacific, are most affected. This has resulted in higher treatment costs and procurement delays. On the positive side, tariffs have encouraged local manufacturing of critical care equipment, boosting domestic innovation and self-reliance in medical device production.

The acute lung injury market research report is one of a series of new reports that provides acute lung injury market statistics, including acute lung injury industry global market size, regional shares, competitors with a acute lung injury market share, detailed acute lung injury market segments, market trends and opportunities, and any further data you may need to thrive in the acute lung injury industry. This acute lung injury market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute lung injury (ALI) is a serious condition marked by widespread inflammation and damage to the lungs, resulting in impaired oxygen exchange. It is often caused by direct factors such as pneumonia or trauma, or indirect factors such as sepsis or pancreatitis. Symptoms of ALI include shortness of breath, low oxygen levels, and respiratory distress.

The main types of acute lung injury are direct injury and indirect injury. Direct injury refers to damage that occurs as an immediate result of an action, event, or incident. Treatment options include mechanical ventilation, pharmacotherapy, fluid management, and others, and are used by end users such as hospitals, clinics, and others.

The acute lung injury market consists of revenues earned by entities by providing services such as intensive care unit (ICU) care, mechanical ventilation, oxygen therapy, extracorporeal membrane oxygenation, and pulmonary rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute lung injury market also includes sales of mechanical ventilators, oxygen therapy products, inhaled medications, sedation and analgesics, and diuretics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.